Doxycycline
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1967
- First approval year
- 1967
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Doxycycline
- Molecular weight
- 462.46
- Structure (SMILES)
- C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O
- doxirobe
- Doxirobe
- doxychel
- Doxychel
- doxycycline
- Doxycycline
- monodox
- Monodox
- oracea
- Oracea
- vibramycin
- Vibramycin
- doxiciclina
- Doxiciclina
- doxirobe
- Doxirobe
- doxycycline
- Doxycycline
- Doxycycline (EMA EPAR: VETERINARY)
- doxycycline (Oracea®) 40 mg modified release as add-on therapy
- doxycycline (Oracea®) 40 mg modified release as monotherapy
- Doxycycline [MI]
- Doxycycline [ORANGE BOOK]
- Doxycycline [USAN]
- Doxycycline [USP MONOGRAPH]
- Doxycycline [VANDF]
- doxycycline ema epar veterinary
- doxycycline mi
- doxycycline monohydrate
- Doxycycline monohydrate
- Doxycycline Monohydrate
- Doxycycline monohydrate [EP IMPURITY]
- Doxycycline monohydrate [EP MONOGRAPH]
- Doxycycline monohydrate [MART.]
- Doxycycline monohydrate [USP-RS]
- Doxycycline monohydrate [VANDF]
- Doxycycline monohydrate [WHO-DD]
And 27 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL1200699
- InChIKey
- XQTWDDCIUJNLTR-CVHRZJFOSA-N
- FDA ingredient codes (UNII)
- N12000U13O
- Applicant
- CHARTWELL RX
- Approval date
- 29 Dec 1989
- Application number
- NDA050641
- Patents
- 1
- Designations
- 0
- Earliest recorded loss of exclusivity
- 19 Dec 2027
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- doxycycline
- Type
- Synthetic organic
- Drug name stem
- -cycline
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- MMP7
- Gene symbol
- MMP7
- Protein identifier
- P09237
- Median affinity
- 4.14
- Affinity units
- pKd
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- MMP8
- Gene symbol
- MMP8
- Protein identifier
- P22894
- Median affinity
- 4.6
- Affinity units
- pIC50
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02358
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02359
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02413
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7J3
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7J7
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7K2
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7K6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L0
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L3
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L8
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M2
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N1
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N4
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7P5
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7Q1
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7Q6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7R5
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7R9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7S3
And 37 more, listed on the interactive page.
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase 13 inhibitor
- Action type
- Inhibitor
- Target
- Collagenase 3
- Mechanism
- Matrix metalloproteinase 7 inhibitor
- Action type
- Inhibitor
- Target
- Matrilysin
- Mechanism
- Matrix metalloproteinase 8 inhibitor
- Action type
- Inhibitor
- Target
- Neutrophil collagenase
- Mechanism
- Matrix metalloproteinase-1 inhibitor
- Action type
- Inhibitor
- Target
- Interstitial collagenase
- Action type
- Inhibitor
- Gene symbol
- MMP7
- Protein identifier
- P09237
- Organism
- Homo sapiens
- Action type
- Inhibitor
- Gene symbol
- MMP8
- Protein identifier
- P22894
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- MMP13
- Protein identifier
- P45452
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Gonorrhea
- Highest recorded phase
- 4
- Condition identifier
- DOID:7551
- Subject identifier
- D006069
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Crohn Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Emphysema
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000464
- Subject identifier
- D004646
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Periodontitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Adenomatous Polyposis Coli
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000662
- Subject identifier
- D011125
- Condition
- Skin Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Anthrax
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000778
- Subject identifier
- D000881
- Condition
- Malaria
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Reperfusion Injury
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002687
- Subject identifier
- D015427
- Condition
- Lymphoma, T-Cell, Cutaneous
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0002913
- Subject identifier
- D016410
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pneumonia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
And 58 more, listed on the interactive page.
- Condition identifier
- DOID_7551
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000545
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000649
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000729
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0000778
- Condition identifier
- EFO_0001068
- Condition identifier
- EFO_0001666
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002913
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0003770
- Highest recorded phase
- 2
And 170 more, listed on the interactive page.
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- cholangitis sclerosing
- Reports
- 46
- Reporting signal score
- 119.819
- Event
- drug hypersensitivity
- Reports
- 1,654
- Reporting signal score
- 2,550.69
- Event
- drug-induced liver injury
- Reports
- 113
- Reporting signal score
- 105.75
- Event
- fall
- Reports
- 17
- Reporting signal score
- 117.322
- Event
- gastrointestinal injury
- Reports
- 54
- Reporting signal score
- 181.137
- Event
- gastrointestinal mucosal necrosis
- Reports
- 57
- Reporting signal score
- 278.636
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 106.51
- Event
- intracranial pressure increased
- Reports
- 64
- Reporting signal score
- 127.919
- Event
- jarisch-herxheimer reaction
- Reports
- 208
- Reporting signal score
- 950.81
- Event
- oesophageal ulcer
- Reports
- 115
- Reporting signal score
- 307.495
- Event
- oesophagitis
- Reports
- 92
- Reporting signal score
- 139.425
- Event
- pancreatitis acute
- Reports
- 164
- Reporting signal score
- 202.191
- Event
- photosensitivity reaction
- Reports
- 133
- Reporting signal score
- 216.055
- Event
- rash
- Reports
- 553
- Reporting signal score
- 161.169
- Event
- vomiting
- Reports
- 577
- Reporting signal score
- 152.606
- NCT00000403
- NCT00000938
- NCT00001101
- NCT02553473
- NCT00007735
- NCT00031499
- NCT04838717
- NCT00066066
- NCT01030666
- NCT02174757
- NCT02538224
- NCT02726646
- NCT03727620
- NCT02735837
- NCT00126399
- NCT00495313
- NCT00855595
- NCT01308619
- NCT01426269
- NCT01872715
- NCT03075891
- NCT03478436
- NCT03655197
- NCT04108897
- NCT05296629
And 102 more, listed on the interactive page.
- Dose
- 100-200mg
- Route
- Intravenous
- How often
- Once or twice daily
- Avoid rapid administration
- Continue for at least 24-48 hours after symptoms subside
- Do not inject intramuscularly or subcutaneously
- Infusion time usually 1-4 hours
- Therapy should not be extended over prolonged periods
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 6
- Polar surface area
- 181.62
- Calculated partition coefficient (ALogP)
- -0.35
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 33
- Molecular formula
- C22H26N2O9
- Natural product
- No
- 0299-3822
- 0527-1335
- 0527-1338
- 0527-1535
- 0527-1537
- 11788-134
- 23155-133
- 23155-134
- 23155-135
- 23155-136
- 33342-346
- 43386-790
- 43386-791
- 43386-792
- 43547-590
- 43598-457
- 46708-249
- 46708-250
- 46708-785
- 50268-280
- 50268-281
- 51407-678
- 51655-350
- 51655-711
- 60687-344
And 88 more, listed on the interactive page.
Liver toxicity assay
- Median
- 53,000
- Mean
- 53,000
- Minimum
- 53,000
- Maximum
- 53,000
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Oral bioavailability
- Median
- 93
- Mean
- 93
- Minimum
- 93
- Maximum
- 93
- Unit
- %
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (306)
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
- A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Novel Combination Oral Agent to Treat Acne Vulgaris
- A Phase II Study of Doxycycline in Relapsed NHL
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
- A Pilot Study of Inflammatory Markers in Alzheimer's Disease
- A Randomized Controlled Trial of Doxycycline Post Exposure Prophylaxis to Prevent Incident Bacterial STIs Among Women in the United States
- A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
- A Study of Continuous Oral Contraceptives and Doxycycline
- A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin
Approved for (14)
- Acne
- Anthrax infection
- Bacterial infectious disease
- Brucellosis
- Gonorrhea
- Malaria
- Ornithosis
- Periodontitis
- Pneumonia
- Rosacea
- Spotted fever
- Tularemia
- Typhus
- Vibrio infectious disease
In development for (64)
- Abdominal aortic aneurysm Phase 2
- AL amyloidosis Phase 2
- Alzheimer disease Phase 3
- Amyloidosis Phase 2
- Atopic eczema Phase 2
- Blepharitis Phase 2
- Borrelia infectious disease Phase 3
- Breast cancer Phase 2
- Cancer Phase 2
- Chlamydia trachomatis infectious disease Phase 3
- Chronic obstructive pulmonary disease Phase 3
- Colorectal adenocarcinoma Phase 2
- Colorectal carcinoma Phase 2
- COVID-19 Phase 3
- Crohn disease Phase 2
- Cystic fibrosis Phase 2
- Dermatitis Phase 2
- Diabetic retinopathy Phase 2
- Dry eye syndrome Phase 2
- Erectile dysfunction Early phase 1
Other linked conditions (10)
- Aortic aneurysm
- Bacterial sexually transmitted disease
- Chronic periodontitis
- Hailey-Hailey disease
- Infertility disorder
- Mycoplasma pneumoniae pneumonia
- Pleural neoplasm
- Rheumatoid arthritis
- Sexually transmitted disease
- Tick-borne relapsing fever